Qiagen launches QIAsymphony RGQ in Europe
This article was originally published in Clinica
Executive Summary
Qiagen has launched the latest device in its QIAsymphony series, the QIAsymphony RGQ, in Europe. US launch is planned in early 2011, the firm told Clinica. The automated molecular diagnostic platform incorporates all workflow steps from sample to detection, and can test one to 72 samples per run. It can also process "an almost unlimited range of sample types", the Dutch company says. The new system can carry out PCR-based tests for disorders including HIV, hepatitis B and C, cytomegalovirus and Epstein-Barr virus. Qiagen is also planning to launch new tests "in the coming months", including ones for EGFR and KRAS gene mutations, and influenza. Older QIAsymphony devices include QIAsymphony AS and QIAsymphony SP.